Noela Rodriguez-Losada

Dr. Noela Rodriguez-Losada

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2007 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CCCarmen Cañibano
Carmen Cañibano
NRNoela Rodriguez-Losada
Noela Rodriguez-Losada
CSCarmen Sáez
Carmen Sáez
STSulay Tovar
Sulay Tovar
MGMontse Garcia‐Lavandeira
Montse Garcia‐Lavandeira
CAClara V Alvarez
Clara V Alvarez
Somatotrophs are the only pituitary cells that express Ret, GFRα1 and GDNF. This study investigated the effects of Ret in a somatotroph cell line, in primary pituitary cultures and in Ret KO mice. Ret regulates somatotroph numbers by inducing Pit‐1 overexpression, leading to increased p53 expression and apoptosis, both of which can be prevented with Ret or Pit‐1 siRNA. The Pit‐1 overexpression is mediated by sustained activation of PKCδ, JNK, c/EBPα and CREB induced by a complex of Ret, caspase 3 and PKCδ. In the presence of GDNF, Akt is activated, and the Pit‐1 overexpression and resulting apoptosis are blocked. The adenopituitary of Ret KO mice is larger than normal, showing Pit‐1 and somatotroph hyperplasia. In normal animals, activation of the Ret/Pit‐1/p53 pathway by retroviral introduction of Ret blocked tumor growth in vivo . Thus, somatotrophs have an intrinsic mechanism for controlling Pit‐1/GH production through an apoptotic/survival pathway. Ret might be of value for treatment of pituitary adenomas.

1 February 2018 in Neuroscience
Verified
Journal Article
Closed access
GBGenevieve Beauvais
Genevieve Beauvais
NRNoela Rodriguez-Losada
Noela Rodriguez-Losada
LYLei Ying
Lei Ying
ZZZuchra Zakirova
Zuchra Zakirova
JWJaime L. Watson
Jaime L. Watson
PGPedro Gonzalez-Alegre
Pedro Gonzalez-Alegre

4 May 2011 in Stem Cells and Development
Verified
Journal Article
Closed access
Juan Antonio MarchalJuan Antonio Marchal
Juan Antonio Marchal
MPManuel Picon-Ruiz
Manuel Picon-Ruiz
MPMacarena Perán
Macarena Perán
CBClara Bueno
Clara Bueno
MJManuel Jiménez-Navarro
Manuel Jiménez-Navarro
AAAntonia Aránega
Antonia Aránega
Endothelial progenitor cells (EPC) represent a relatively rare cell population, and expansion of sufficient cell numbers remains a challenge. Nevertheless, human adipose-derived stem cells (hASC) can be easily isolated and possess the ability to differentiate into endothelial cells. Here, we propose the isolation and characterization of multipotent endothelial-like cells (ME-LC) with the capacity to maintain their vascular progenitor properties for long periods. hASC were isolated from lipoaspirates and cultured through distinct consecutive culture stages for 2 months to enrich ME-LC: first in Dulbecco's modified Eagle's medium–fetal bovine serum (stage I), followed by a stage of culture in absent of fetal bovine serum (stage II), a culture in SFO3 medium (stage III), and, finally, the culture of ME-LC into collagen IV-coated flasks in endothelial growth medium (EGM-2) (stage IV). ME-LC display increased expression levels of endothelial and hematopoietic lineage markers (CD45, KDR, and CXCR4) and EPC markers (CD34 and CD133), whereas the expression of CD31 was barely detectable. Reverse transcription (RT)-polymerase chain reaction assays showed expression of genes involved in early stages of EPC differentiation and decreased expression of genes associated to differentiated EPC ( TIE-2 , DLL4, and FLT-1 ). ME-LC formed capillary-like structures when grown on Matrigel, secreted increased levels of stromal cell-derived factor-1 (SDF-1), and showed the ability to migrate attracted by SDF-1, vascular endothelial growth factor, and hematopoietic growth factor cytokines. Importantly, ME-LC retained the capacity to differentiate into cardiomyocyte-like cells. We present a simplified and efficient method to generate large numbers of autologous ME-LC from lipoaspirates-derived hASC, opening up potential cell-based therapies for cardiovascular regenerative medicine.

11 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DHDominic Henn
Dominic Henn
DBDoris Bandner-Risch
Doris Bandner-Risch
HPHilja Perttunen
Hilja Perttunen
WSWolfram Schmied
Wolfram Schmied
CPCarlos Porras
Carlos Porras
HSHans-Joachim Schäfers
Hans-Joachim Schäfers
Hypertension and congenital aortic valve malformations are frequent causes of ascending aortic aneurysms. The molecular mechanisms of aneurysm formation under these circumstances are not well understood. Reference genes for gene activity studies in aortic tissue that are not influenced by aortic valve morphology and its hemodynamic consequences, aortic dilatation, hypertension, or antihypertensive medication are not available so far. This study determines genes in ascending aortic tissue that are independent of these parameters. Tissue specimens from dilated and undilated ascending aortas were obtained from 60 patients (age ≤70 years) with different morphologies of the aortic valve (tricuspid undilated n = 24, dilated n = 11; bicuspid undilated n = 6, dilated n = 15; unicuspid dilated n = 4). Of the studied individuals, 36 had hypertension, and 31 received ACE inhibitors or AT1 receptor antagonists. The specimens were obtained intraoperatively from the wall of the ascending aorta. We analyzed the expression levels of 32 candidate reference genes by quantitative RT-PCR (RT-qPCR). Differential expression levels were assessed by parametric statistics. The expression analysis of these 32 genes by RT-qPCR showed that EIF2B1, ELF1, and PPIA remained constant in their expression levels in the different specimen groups, thus being insensitive to aortic valve morphology, aortic dilatation, hypertension, and medication with ACE inhibitors or AT1 receptor antagonists. Unlike many other commonly used reference genes, the genes EIF2B1, ELF1, and PPIA are neither confounded by aortic comorbidities nor by antihypertensive medication and therefore are most suitable for gene expression analysis of ascending aortic tissue.

1 May 2015 in Cytokine
Verified
Journal Article
Closed access
FCFernando Cabrera-Bueno
Fernando Cabrera-Bueno
CMCarmen Medina-Palomo
Carmen Medina-Palomo
ARAmalio Ruiz-Salas
Amalio Ruiz-Salas
AFAna Flores
Ana Flores
NRNoela Rodriguez-Losada
Noela Rodriguez-Losada
JAJavier Alzueta
Javier Alzueta

10 December 2009 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
NANatália António
Natália António
Rosa FernandesRosa Fernandes
Rosa Fernandes
NRNoela Rodriguez-Losada
Noela Rodriguez-Losada
MJManuel Jiménez-Navarro
Manuel Jiménez-Navarro
APArtur Paiva
Artur Paiva
LPLuís A. Providência
Luís A. Providência